There were 2,481 press releases posted in the last 24 hours and 441,564 in the last 365 days.

Contact

Please use this form to send email to PR contact of this press release:
Rafael Pharmaceuticals Announces Activation of Second Clinical Trial Site for the Phase I Study of CPI-613 in Patients with Relapsed or Refractory T-Cell Lymphoma

TO:



FROM:

Please check your email address!

Please, do not fill this field.

Please, do not change this field.

Please, do not fill if your javascript is turned off.

captcha image